Statins induce hepatotoxicity via reduced levels of Coenzyme Q10, inflammation, and oxidative stress. Coenzyme Q10 is antiapoptotic and possesses the antioxidative potential and hence has been studied for its hepatoprotective potential. However, owing to the differing mechanisms of prevention of damage and its reversal, we hypothesize that coenzyme Q10 might not have the same efficacy as a protective versus a therapeutic agent. An experimental study of 3 weeks was conducted on a sample of 35 mice, randomly divided into 7 groups. Group 1 was used as control. Group 2 received 50mg/kg/day of simvastatin intraperitoneally (I/P). Group 3 received I/P 50mg/kg/day rosuvastatin. Group 4 received 50mg/kg/day of simvastatin+10mg/kg of coenzyme Q10. Group 5 received 50mg/kg/day of rosuvastatin+10mg/kg of coenzyme Q10 I/P. In group 6 simvastatin 50mg/kg & 7 rosuvastatin 50mg/kg was given for a week, while 10mg/kg of Coenzyme Q10 was started in the 2nd week and continued for 2 weeks. Hepatic damage was observed in groups 2,3,6 and 7 indicated by raised alanine transaminase levels of 320.4, 179.8, 301.4, and 186.8 and raised aspartate aminotransferase levels of 320, 196, 421.4, and 307.6. Bilirubin stayed within normal limits. This study concludes that Coenzyme Q10 prevents statin-induced liver damage but has no role as a therapeutic agent once the liver damage has occurred.